Browse the full insider trade history of AGIOS PHARMACEUTICALS INC, a listed issuer based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Market capitalisation: €1.7bn. The latest transaction was reported on 10 February 2016 (Levée d'options). Among the most active insiders: Biller Scott. All data is free.
13
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate AGIOS PHARMACEUTICALS INC Buy (bullish), based on 8 analysts. Average price target: US$40.88.
22Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 20,052 of 24,985 companies
30.4
score / 100
Value
9
Quality
52
FCF yld-23%
Earn yld-24%
EV/EBITDA·
ROE-33%
Gross mgn88%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
AGIOS PHARMACEUTICALS INC is a biopharmaceutical company focused on developing treatments for rare diseases and cancer. The company is dedicated to the discovery and commercialization of innovative medicines.